- Overview
- Bayer Group
- Stock
- Bonds
- Reports
- Annual Stockholders’ Meeting 2015
- Events
- News
- Investor News
- Ad-hoc Publications
- Press
- Archive
- Overview
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Ad-hoc 2014
- Ad-hoc 2013
- Ad-hoc 2012
- Ad-hoc 2011
- Ad-hoc 2010
- Ad-hoc 2009
- Ad-hoc 2008
- Ad-hoc 2007
- Ad-hoc 2006
- Ad-hoc 2005
- Ad-hoc 2004
- Ad-hoc 2003
- Ad-hoc 2002
- Ad-hoc 2001
- Ad-hoc 2000
- Ad-hoc 1999
- Ad-hoc 1998
- Handouts
- Downloads
Ad-hoc Messages 2010
Here you find Ad-hoc messages of year 2010.
To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.
| 2010 | |
|---|---|
| October 31, 2010 Bayer AG: Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin | |
| August 4, 2010 Bayer AG: Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study |
Investor News issued in year 2010 can be found here.
Publications of the previous years are offered in the Archive Overview.
